JT

Jonathan Tobin

Non Executive Director at Adendra Therapeutics

London, England

Overview

Work Experience

  • Partner

    2021 - Current

    I'm focused on leading investments in biotech companies globally. jtobin@bcpvc.com

  • Investor-in-Residence

    2023

    As investor-in-residence I am advising the CRH Seed fund team on their early stage investments in start-ups based on the ground breaking research emerging from Cancer Research UK laboratories.

  • Non Executive Director

    2024

    Non-exec director representing Cancer Research Horizons

  • Non Executive Director

    2023

  • Non Executive Director

    2021

  • Non Executive Director

    2022

    First-in-class anti-GDF15 mAb in Phase 2 in solid tumour patients

  • Non Executive Director

    2022

  • Non Executive Director

    2022

  • Member of the Investment Advisory Committee

    2020

    KHAN-I is a new fund backed by the Max Planck Foundation, European Investment Fund, and Austrian government to back early stage drug discovery projects originating from Germany and Austria to create new biotech opportunities.

  • Commercial Partnerships Advisor

    2021 - 2021

    Large consultancy project advising Genomics England on part of their commercial strategy

Relevant Websites